JP2019112416A5 - - Google Patents

Download PDF

Info

Publication number
JP2019112416A5
JP2019112416A5 JP2019026073A JP2019026073A JP2019112416A5 JP 2019112416 A5 JP2019112416 A5 JP 2019112416A5 JP 2019026073 A JP2019026073 A JP 2019026073A JP 2019026073 A JP2019026073 A JP 2019026073A JP 2019112416 A5 JP2019112416 A5 JP 2019112416A5
Authority
JP
Japan
Prior art keywords
entinostat
administration
exemestane
combination
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019026073A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019112416A (ja
JP6860949B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2019112416A publication Critical patent/JP2019112416A/ja
Publication of JP2019112416A5 publication Critical patent/JP2019112416A5/ja
Application granted granted Critical
Publication of JP6860949B2 publication Critical patent/JP6860949B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019026073A 2013-05-03 2019-02-15 癌の処置方法 Active JP6860949B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361819505P 2013-05-03 2013-05-03
US61/819,505 2013-05-03

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2016512076A Division JP2016522188A (ja) 2013-05-03 2014-05-02 癌の処置方法

Publications (3)

Publication Number Publication Date
JP2019112416A JP2019112416A (ja) 2019-07-11
JP2019112416A5 true JP2019112416A5 (cg-RX-API-DMAC7.html) 2019-09-19
JP6860949B2 JP6860949B2 (ja) 2021-04-21

Family

ID=51843995

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016512076A Pending JP2016522188A (ja) 2013-05-03 2014-05-02 癌の処置方法
JP2019026073A Active JP6860949B2 (ja) 2013-05-03 2019-02-15 癌の処置方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2016512076A Pending JP2016522188A (ja) 2013-05-03 2014-05-02 癌の処置方法

Country Status (6)

Country Link
EP (1) EP2991650A4 (cg-RX-API-DMAC7.html)
JP (2) JP2016522188A (cg-RX-API-DMAC7.html)
KR (1) KR102337598B1 (cg-RX-API-DMAC7.html)
CN (1) CN105492007A (cg-RX-API-DMAC7.html)
HK (1) HK1223547A1 (cg-RX-API-DMAC7.html)
WO (1) WO2014179738A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3313433A4 (en) * 2015-06-29 2019-01-02 Syndax Pharmaceuticals Inc. Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of cancer
WO2018016563A1 (en) * 2016-07-20 2018-01-25 Eisai R&D Management Co., Ltd. Use of eribulin and histone deacetylase inhibitors in the treatment of cancer
US12168054B2 (en) 2017-05-19 2024-12-17 Syndax Pharmaceuticals, Inc. Method of treating cancer using a combination of entinostat and an anti-CSF-1R antibody
CN112601516A (zh) * 2018-06-06 2021-04-02 艾尼纳制药公司 治疗与s1p1受体相关的病况的方法
RU2680603C1 (ru) * 2018-11-08 2019-02-25 Ильясов Шамиль Сионович Применение 3-о-сульфамата-16,16-диметил-d-гомоэквиленина для лечения онкологических заболеваний

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0608039A2 (pt) * 2005-03-11 2009-06-16 Univ Colorado células cancerìgenas sensìveis aos inibidores da histona deacetilase
WO2008008434A1 (en) * 2006-07-11 2008-01-17 Mutual Pharmaceutical Company, Inc. Controlled-release formulations
US20100305167A1 (en) * 2007-11-19 2010-12-02 Syndax Pharmaceuticals, Inc. Administration of an Inhibitor of HDAC
CA2719115A1 (en) * 2008-03-07 2009-09-11 Pfizer Inc. Methods, dosage forms, and kits for administering ziprasidone without food
US20110182888A1 (en) * 2008-04-08 2011-07-28 Peter Ordentlich Administration of an Inhibitor of HDAC, an Inhibitor of HER-2, and a Selective Estrogen Receptor Modulator
WO2013033656A1 (en) * 2011-09-02 2013-03-07 Syndax Pharmaceuticals, Inc. Methods for the treatment of breast cancer

Similar Documents

Publication Publication Date Title
JP2019112416A5 (cg-RX-API-DMAC7.html)
US9763898B2 (en) Nutritional composition for promoting musculoskeletal health in patients with inflammatory bowel disease (IBD)
JP2019048843A5 (cg-RX-API-DMAC7.html)
JP2022121594A5 (cg-RX-API-DMAC7.html)
JP2023107883A5 (cg-RX-API-DMAC7.html)
JP2020519295A5 (cg-RX-API-DMAC7.html)
JP2023024704A (ja) 絶食条件下でのタシメルテオンの投与
JP2015503593A5 (cg-RX-API-DMAC7.html)
JP2014525465A5 (cg-RX-API-DMAC7.html)
JP2013529665A5 (cg-RX-API-DMAC7.html)
JP2016522188A5 (cg-RX-API-DMAC7.html)
JP2020532531A5 (cg-RX-API-DMAC7.html)
Mantovani Randomised phase III clinical trial of 5 different arms of treatment on 332 patients with cancer cachexia.
JP2017536380A (ja) 15−hepeを含む組成物、およびそれを用いて線維症を処置または防止する方法
JP2020500864A5 (cg-RX-API-DMAC7.html)
WO2017148129A1 (zh) 一种用于治疗恶病质的药物组合物及其应用
CN104490920A (zh) 一种治疗口腔溃疡的贴膜及其制备方法
JP2016539149A5 (cg-RX-API-DMAC7.html)
CN112823795A (zh) 一种特发性肺纤维化药物组合及其应用
Jagmeet et al. Kanchanar guggulu and Varunadi kashaya in hypothyroidism-a case study
RU2007105789A (ru) Способ коррекции недифференцированной дисплазии соединительной ткани
RU2016136666A (ru) Составы на основе прогестерона
CN105050607B (zh) 用于治疗关节炎和骨关节炎的方法和组合物
Teng et al. Neuroprotection of maslinic acid, a novel glycogen phosphorylase inhibitor, in type 2 diabetic rats
JPH0466528A (ja) 炎症性腸疾患用油脂組成物